Licopid (glycopin) / Peptek - LARVOL DELTA

Restoration of innate immunity receptors under the action of muramyl peptides reduces depression and anxiety at the stage of rehabilitation after COVID-19 (EAACI 2022) - "Method Patients who underwent mild to moderate COVID-19 (N=60, mean age 54 ± 11.7 years) were randomized to the study group (30 people, 15 men and 15 women) who received 2 courses of licopid 1 mg twice per day and a comparison group (30 people, 15 men and 15 women)...In the comparison group, there was no improvement in the psycho-emotional state of patients. Conclusion In this study, for the first time, it was found that the correction of immunological parameters when exposed to GMDP after a previous illness contributed not only to a decrease in the frequency and severity of respiratory infections, but also to an improvement in the psycho-emotional state of patients, and a decrease in anxiety and depression."

Immune Modulation • Immunology • Inflammation • CD8 • TLR4 • TLR9

Pathogenetic Therapy of Psoriasis by Muramyl Peptide. (PubMed, Front Immunol) - "The aim of this study was to survey the clinical efficacy and safety of muramyl peptide-the ligand of the receptors of innate immunity (drug Licopid, AO Peptek, Moscow, Russia) in patients with psoriasis...The conducted studies showed that monotherapy with muramyl peptide stopped the clinical manifestations of psoriasis, normalized the processes of cytokine-dependent [interleukin (IL)-4, IL-10, IL-12, tumor necrosis factor alpha (TNF-α)] regulation of the immune response and nonspecific resistance, expressed in a decreasing amount of serum antigens sCD54 [soluble intercellular adhesion molecule-1 (sICAM-1)] to reference values (p ≤ 0.01). Taken together, our research demonstrated the effectiveness of therapy with muramyl peptide and moreover, that elevated levels of sCD54 and MIF (p ≤ 0.01) in the serum of patients with psoriasis considered as potential biomarkers of the severityof psoriasis and control over their dynamics have prognostic significance in determining the..."

Biomarker • Journal • Dermatology • Gene Therapies • Immunology • Psoriasis

Determination of the immunostimulatory drug - Glucosoaminyl-Muramyl-Dipeptide - in human plasma using high performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. (PubMed, Biomed Chromatogr) - "The developed and validated HPLC-MS/MS method was successfully used to obtain the plasma pharmacokinetic profiles of GMDP distribution in human plasma."

Journal • PK/PD data • Immune Modulation • Inflammation